Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?

Shift In 1L NSCLC Standard Of Care

 
• By Dexter Jie Yan
  
arm wrestling
China-originated anti-PD-(L)1/VEGF bispecific antibodies will be wrestling with each other in the coming years. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

More from R&D